山东威高集团医用高分子制品股份有限公司（01066）于2026年1月12日发布翌日披露报表，公告当日以每股5.25至5.35港元在港交所回购股份64万股，占回购前已发行股本约0.0143%，涉资约339.14万港元。公司于回购前的已发行股份数（不包括库藏股）为4,487,159,124股，库藏股为35,173,200股，回购后分别变动至4,486,519,124股及35,813,200股。
该份公告显示，本次回购根据2025年5月27日获股东大会通过的购回授权进行，授权范围可回购股份总数为451,560,392股，累计已回购股份29,164,800股，占授权通过当日已发行股份总数约6.4587%。公告并提及公司遵守上市规则及相关法规，回购程序已获公司董事会正式批准。
公司同时确认相关法律及手续均已符合香港联合交易所有限公司证券上市规则等规定。本公告由公司秘书黄妙玲签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.